Ipamorelin
Also: Ipamorelin acetate, NNC 26-0161
This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more
Ipamorelin is a synthetic pentapeptide categorized in the research literature as a growth hormone secretagogue and discussed primarily in preclinical and laboratory settings. It is described as an agonist of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a) that has been reported to influence endogenous growth hormone release in animal and in-vitro models. The available evidence is limited and largely non-clinical, and findings should be interpreted cautiously given study-design and translation constraints. This profile is provided for research and educational reference only and is not a recommendation for any use.
Mechanism as described in the literature
Ipamorelin is a synthetic pentapeptide described in the research literature as a growth hormone secretagogue that acts as an agonist at the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a). In preclinical and in-vitro studies, binding at this receptor on pituitary and hypothalamic cells has been reported to influence the release of endogenous growth hormone. These are mechanistic observations drawn from laboratory models and do not represent outcomes in humans.
Mechanistic reports characterize it as relatively selective within the growth hormone-releasing peptide (GHRP) class, with some studies describing limited measured effect on the release of other pituitary hormones such as cortisol, ACTH, and prolactin compared with certain earlier secretagogues. Such selectivity descriptions are pharmacological characterizations reported in animal and cell-based work, not safety, tolerability, or benefit conclusions. Their relevance to other species or contexts is not established and requires careful interpretation.
Research areas
- Ghrelin receptor (GHS-R1a) signaling characterized in vitro
- Pituitary growth hormone release in preclinical animal models
- Selectivity profiling within the growth hormone-releasing peptide (GHRP) class
- Comparative neuroendocrine pharmacology in laboratory models
- Analytical identity and purity testing visibility for research material
Documentation notes
References
Frequently asked questions
What kind of compound is Ipamorelin?+
It is generally described in the research literature as a synthetic pentapeptide and a growth hormone secretagogue that acts at the ghrelin (GHS-R1a) receptor. This classification is descriptive and based on preclinical and mechanistic studies, not on clinical outcome claims.
Is there strong human evidence for Ipamorelin?+
No. The available literature is predominantly preclinical (animal and in-vitro). Human data are limited, and any conclusions about outcomes would be premature and require careful interpretation due to study-design and translation limitations.
Is Ipamorelin the same as a blend such as GLOW or KLOW?+
No. Ipamorelin is a single defined peptide, whereas terms like GLOW or KLOW refer to multi-ingredient combinations whose composition varies between sources. Any such blend reference is ambiguous and should be verified editorially against the original source before being relied upon.